<DOC>
	<DOCNO>NCT00418184</DOCNO>
	<brief_summary>The primary objective trial determine whether oral administration Phosphatidylserine-Omega3 would significantly improve clinical symptom child suffer ADHD . Both behavior academic achievement aspect evaluate . In addition , intend measure side-effects adverse event examine possible correlation biochemical behavioral alteration .</brief_summary>
	<brief_title>The Efficacy Safety Phosphatidylserine-Omega3 Children With Attention-Deficit/ Hyperactivity Disorder</brief_title>
	<detailed_description>This study single-center , double-blind , randomize , placebo-controlled 15-weeks duration trial ass safety efficacy Phosphatidylserine-Omega3 child diagnose ADHD , accord DSM-IV . Following screening , subject randomize one two treatment group : Phosphatidylserine-Omega3 placebo , 2:1 manner . This follow open-label extension , Phosphatidylserine-Omega3 administer eligible participant . Primary measure attention behavior evaluate use Conners Rating Scale ( CRS ) teacher- rating scale . As secondary endpoint , attention behavior measure CRS strength difficulty questionnaire ( SDQ ) parental- SDQ teacher-rating scale , assessment continuous performance test ( TOVA ) , parental Child Health questionnaire ( CHQ ) . Improvement ADHD symptom evaluate Clinical Global Impression - Improvement ( CGI-I ) . Finally , tolerability monitor use Barkley Side Effects Rating Scale ( SERS ) biochemical parameter , fatty acid profile monoamine metabolite assess well .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Parental write informed consent . 2 . Having teacher familiar child parent willing participate . 3 . Age : 13≥ year ≥6 4 . Gender : male female 5 . Diagnosis : ADHD diagnose : Teacherrated AttentionDeficit/ Hyperactivity Disorder Rating ScaleIV ( ADHDRSIV ) School Version least 1.5 standard deviation ( SD ) norm patient 's age gender , Confirmed assessment Schedule Affective Disorders Schizophrenia SchoolAge ChildrenPresent Lifetime Version ( KSADSPL ) , 6 . Clinical Global Impression Severity illness ( CGIS ) rating 4 high ( moderately ill bad ) , 7 . Language : Subjects , parent , teacher must able read , write speak Hebrew 8 . Normal weight height accord Israeli standard 9 . Attending fulltime school . 1 . Females reach menarche present three regular menstrual cycle ; definition regular menstrual cycle : average length cycle 22 41 day , either none single cycle length le 22 41 day past year 2 . History current diagnosis serious systemic ( e.g. , diabetes , hyper/hypothyroidism , etc . ) neurological condition ( e.g. , epilepsy , brain tumor , etc . ) 3 . Failed respond 2 adequate course ( dose duration ) stimulant therapy ADHD 4 . Pervasive developmental disorder Nonverbal Learning Disability 5 . Schizophrenia , psychotic disorder ( DSMIV axis I ) 6 . Any evidence suicidal risk , current psychiatric comorbidity require psychiatric pharmacotherapy 7 . History alcohol substance abuse define DSMIV criterion 8 . Consumption &gt; 250 mg/day caffeine 9 . Blindness 10 . History allergic reaction sensitivity marine product ( fish seafood ) , soy corn well illness may jeopardize participant health limit successful trial completion .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>ADHD</keyword>
	<keyword>inattentive</keyword>
	<keyword>impulsive</keyword>
	<keyword>hyperactive</keyword>
	<keyword>poor academic performance</keyword>
	<keyword>poor self-discipline</keyword>
	<keyword>low self-esteem</keyword>
</DOC>